Unity Biotechnology (NASDAQ:UBX) has been given a $14.00 target price by equities researchers at Morgan Stanley in a note issued to investors on Monday, TipRanks reports. The firm presently has a “buy” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 80.41% from the stock’s previous close.
Separately, Zacks Investment Research lowered Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $19.50.
Unity Biotechnology stock traded down $0.31 on Monday, hitting $7.76. 7,509 shares of the stock traded hands, compared to its average volume of 395,174. The stock has a market capitalization of $356.13 million, a price-to-earnings ratio of -3.06 and a beta of -0.24. The firm has a fifty day moving average of $8.58. Unity Biotechnology has a 1 year low of $7.30 and a 1 year high of $24.56.
Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC increased its holdings in Unity Biotechnology by 18.2% in the 1st quarter. FMR LLC now owns 4,551,523 shares of the company’s stock worth $36,913,000 after buying an additional 700,500 shares in the last quarter. BlackRock Inc. increased its holdings in Unity Biotechnology by 441.2% in the 4th quarter. BlackRock Inc. now owns 1,850,882 shares of the company’s stock worth $30,095,000 after buying an additional 1,508,908 shares in the last quarter. Northern Trust Corp increased its holdings in Unity Biotechnology by 293.7% in the 4th quarter. Northern Trust Corp now owns 230,152 shares of the company’s stock worth $3,742,000 after buying an additional 171,696 shares in the last quarter. Geode Capital Management LLC increased its holdings in Unity Biotechnology by 151.0% in the 4th quarter. Geode Capital Management LLC now owns 145,488 shares of the company’s stock worth $2,365,000 after buying an additional 87,519 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Unity Biotechnology by 273.3% in the 4th quarter. Bank of New York Mellon Corp now owns 58,620 shares of the company’s stock worth $953,000 after buying an additional 42,915 shares in the last quarter. 38.21% of the stock is owned by hedge funds and other institutional investors.
Unity Biotechnology Company Profile
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.
See Also: What does earnings per share mean?
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.